Haematologica EWOG-MDS website
HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Roti, G
Right arrow Articles by Mecucci, C
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Roti, G
Right arrow Articles by Mecucci, C
Haematologica, Vol 90, Issue 8, 1139-1141
Copyright © 2005 by Ferrata Storti Foundation

Case Reports

e6a2 BCR/ABL1 fusion with cryptic der(9)t(9;22) deletions in a patient with chronic myeloid leukemia

G Roti, R La Starza, P Gorello, E Gottardi, B Crescenzi, MF Martelli, and C Mecucci

This is the first report of e6a2 and e1a2 BCR/ABL1 positive chronic myeloid leukemia (CML) with cryptic deletions of the 5'ABL1 and 3'BCR in separate clones which differ in genomic regions of the deleted der(9). Both deletions were detected throughout monitoring. Imatinib mesylate stabilized this CML with rare genetic aberrations for a relatively long time.


This article has been cited by other articles:


Home page
 BloodHome page
D. S. Ritchie, M. McBean, D. A Westerman, S. Kovalenko, J. F. Seymour, and A. Dobrovic
Complete molecular response of e6a2 BCR-ABL-positive acute myeloid leukemia to imatinib then dasatinib
Blood, March 1, 2008; 111(5): 2896 - 2898.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
Copyright © 2005 by the Ferrata Storti Foundation.